PUBLISHER: The Insight Partners | PRODUCT CODE: 2070338
PUBLISHER: The Insight Partners | PRODUCT CODE: 2070338
The Americas Total IV Solutions Market is anticipated to grow from US$ 4.91 billion in 2025 to US$ 10.41 billion by 2034, with a CAGR of 8.7% during 2026-2034.
The total IV solutions market growth is attributed to rising chronic disease prevalence and diabetes-related intravenous therapy needs, increasing hospitalization rates, surgical procedures, and emergency room visits, as well as the expansion of home healthcare and outpatient infusion services drive the adoption of total IV solutions.
The Americas total IV solutions market includes all intravenous fluids and drug delivery solutions used in hospitals, clinics, ambulatory surgical centers, and home care settings. Premixed IV drug solutions represent a key growth segment within the market due to their ready-to-use format, reduced pharmacy preparation requirements, lower risk of medication errors, and improved clinical efficiency. These solutions contain active pharmaceutical ingredients such as Paracetamol, Ciprofloxacin, Fluconazole, and Dexmedetomidine.
Non-premixed IV products, in comparison, require compounding from base fluids, concentrates, and admixture-based solutions before administration. IV solutions support essential healthcare functions, including fluid and electrolyte balance, medication delivery, nutritional support, pain management, anti-infective treatment, and sedation. Hospitals continue to dominate market demand because of increasing patient admissions, rising surgical volumes, and the growing burden of chronic diseases, while home care and outpatient facilities are increasingly adopting premixed IV solutions for efficient treatment delivery.
The total IV solutions market in North America is segmented into the US, Canada, and Mexico. North America is leading the total IV solutions market, driven by rising burden of chronic and infectious diseases, increasing hospitalizations, and continuous technological innovation in infusion systems. The Centers for Disease Control and Prevention (CDC) estimates that in 2023, over 39,000 new cases of HIV occurred in the US, with an estimated 1.13 million people currently receiving treatment for HIV (long-term IV) and require ongoing support through infusion-based therapies. Chronic diseases account for nearly 70% of all deaths in the US, thus providing continued demand for IV-based therapies for chronic conditions including but not limited to cancer, diabetes, and cardiovascular disease.
As of 2024, the CDC reported that linkage to care for HIV has increased to over 80%, providing evidence that the treatment portion of the HIV treatment continuum has grown considerably and reinforcing the necessity for infusion therapies in overall healthcare systems. Additionally, ongoing rates of hospital-acquired infections in the US continue to be a significant issue, as more than 250,000 bloodstream infections are associated with IV devices each year. This creates a greater need for advanced infusion solutions and the utilization of safe infusion practices. New product innovations, such as smart infusion pumps, ultrasound-guided access devices, and biologically resistant IV disposables, are providing hospitals and home care environments with greater safety and efficiency, ultimately increasing use.
Increased Use of IV Therapy in Oncology and Specialty Treatments to Provide Market Opportunities in Future
IV solutions are currently a very important part of the treatment of patients receiving treatment for cancer (oncology), immunotherapy and specialty care throughout the Americas. According to the Pan American Health Organization (PAHO), cancer is one of the leading causes of death in the Americas and will produce millions of new cases throughout the US, Brazil and Mexico (2023- 2025). Current guidelines for oncology treatment require the vast majority of doses of chemotherapy (or other treatments) will be given thru an IV. The US responded with an analysis from the Centres For Disease Control and Prevention (CDC) in 2024, indicating cancer is still placing an enormous burden on both (outpatient and inpatient) infusion services. Brazil's national cancer institute (Instituto Nacional de Cancer) reported in 2023-2024 that patient access to chemotherapy services has increased, resulting in a corresponding increase in the use of IV solutions. In Argentina, Chile and Colombia, there has been an expansion of oncology treatment access programs from 2023-2025 that resulted in an increase in the number of patients receiving IV-based oncologic treatments, as the growing use of IV solutions reflects a shift in therapeutic applications so that IV solutions have become an integral (rather than merely supportive care) part of complex treatment regimens in specialized care settings, resulting in increases in both the volume and frequency of use of IV solutions.
The US Food and Drug Administration, American Society of Health-System Pharmacists, Centers for Disease Control and Prevention, DATASUS, Pan American Health Organization are among the primary and secondary sources referred to while preparing the total IV solutions market report.
Amanta Healthcare financials are not available in the public domain.